Inclusion Criteria:  Histologically or cytologically confirmed solid tumors documented as advanced or metastatic disease; Subjects must be considered relapsed or refractory to standard therapies, have been intolerant to standard therapies, or have refused standard therapy; ECOG: 0-1; Adequate organ and bone marrow function; sign an informed consent.  Exclusion Criteria:  Patients with brain malignant tumor or active CNS metastasis; UGT1A1*28 homozygous mutants; Clinically significant GI disorders; Significant cardiovascular disease; Active infection or uncontrolled fever; Pregnant or breast feeding patients; Allergic to a drug ingredient or component; The investigators determined that other conditions were inappropriate for participation in this clinical trial.